International Assets Investment Management LLC Acquires New Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

International Assets Investment Management LLC acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,997 shares of the company’s stock, valued at approximately $455,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in VRDN. Quest Partners LLC grew its holdings in Viridian Therapeutics by 344.0% during the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after purchasing an additional 4,692 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in Viridian Therapeutics by 19.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after purchasing an additional 799 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Viridian Therapeutics by 24.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after purchasing an additional 2,359 shares during the last quarter. AlphaCentric Advisors LLC grew its holdings in Viridian Therapeutics by 108.3% during the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock valued at $163,000 after purchasing an additional 6,500 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in Viridian Therapeutics by 14.7% during the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after purchasing an additional 1,688 shares during the last quarter.

Viridian Therapeutics Stock Up 4.2 %

Shares of VRDN stock opened at $24.27 on Thursday. The stock has a market cap of $1.55 billion, a P/E ratio of -5.71 and a beta of 1.10. Viridian Therapeutics, Inc. has a one year low of $11.40 and a one year high of $25.39. The stock has a fifty day moving average price of $21.23 and a 200 day moving average price of $16.46. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.82 and a quick ratio of 15.82.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.15). The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. Analysts predict that Viridian Therapeutics, Inc. will post -3.94 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Fairmount Funds Management Llc acquired 1,600,000 shares of the business’s stock in a transaction on Friday, September 13th. The stock was bought at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the acquisition, the director now owns 3,445,813 shares in the company, valued at $64,608,993.75. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Fairmount Funds Management Llc acquired 1,600,000 shares of the business’s stock in a transaction on Friday, September 13th. The stock was bought at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the acquisition, the director now owns 3,445,813 shares in the company, valued at $64,608,993.75. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Stephen F. Mahoney acquired 21,400 shares of the business’s stock in a transaction on Friday, September 27th. The shares were bought at an average cost of $23.33 per share, with a total value of $499,262.00. Following the completion of the acquisition, the chief executive officer now owns 21,400 shares of the company’s stock, valued at approximately $499,262. The disclosure for this purchase can be found here. Insiders bought a total of 1,626,400 shares of company stock valued at $30,616,312 over the last ninety days. 0.65% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have commented on VRDN. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Viridian Therapeutics in a report on Tuesday, September 10th. BTIG Research increased their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, September 26th. Wedbush restated an “outperform” rating and issued a $42.00 price objective on shares of Viridian Therapeutics in a research note on Monday, July 29th. The Goldman Sachs Group raised their price objective on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Monday, October 28th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $35.80.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.